CoagulationDisorders near Port Charlotte, FL

Care Philosophy: Dr Locke is a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy. He leads the Immune Cell Therapy (ICE-T) initiative at Moffitt, an integrated cross-departmental translational team. Dr Locke is a clinical research leader in the field of Chimeric Antigen Receptor (CAR) T cell therapy, acting as a national P.I. for several pivotal trials of anti-CD19 CARs for lymphoma. In addition, Dr Locke is translating findings from his laboratory into new cellular immunotherapies such as the Moffitt created whole protein survivin tumor vaccine for multiple myeloma. Dr Locke graduated with a B.S.

Care Philosophy: Dr Isenalumehe earned her MD from Sophie Davis School of Biomedical Education, CUNY Medical College, City College of New York (BA/MD Program) / Albany Medical College, New York and her MS degree in Clinical and Biomedical Investigation from the University of Southern California, Los Angeles. She completed a combined Internal Medicine and Pediatric Residency at NJMS-Rutgers (former: University of Medicine and Dentistry of New Jersey, Newark, where she also served as Internal Medicine-Pediatrics Chief Resident. She completed a Pediatric Hematology-Oncology Fellowship at Children's Hospital of Los Angeles, University of Southern California, where she also served as Chief Fellow.

Care Philosophy: Dr Celeste Bello isa double board-certified hematologist and medical oncologist, and a senior member in the Malignant Hematology program at Moffitt Cancer Center. She joined the faculty at Moffitt Cancer Center in 2008 after completing her fellowship at the University of South Florida. Dr Bello has developed special expertise in managing patients with Hodgkin's and non-Hodgkin's lymphomas, a special category within the broader group of hematologic (blood) malignancies. Examples of non-Hodgkin's lymphomas include follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma.

Care Philosophy: At Moffitt Cancer Center, we are working tirelessly in the areas of patient care, research and education to advance one step further in fighting cancer. As a National Cancer Institute-designated Comprehensive Cancer Center, we are committed to the health and safety of our patients and dedicated to providing expert cancer care. From enhanced quality of life to complete remission, Moffitt is Florida's top choice aiming to achieve the best outcome for each patient.

Biography: Dr. Qamar Khan, MD is a Hematology Specialist who practices in Celebration, FL. He is 62 years old and has been practicing for 35 years. Dr. Qamar Khan, MD is affiliated with AdventHealth Orlando.

Care Philosophy: Dr Blue earned his MD at Meharry Medical College, Nashville, Tennessee. Dr Blue completed an Internal Medicine Residency in the Department of Medicine at Washington University School of Medicine, St. Louis, Missouri, and d a Hematology/Oncology Fellowship in the Department of Medicine at Saint Louis University School of Medicine. Dr Blue recently completed a Blood and Marrow Transplant and Cellular Immunotherapy Fellowship at Moffitt Cancer Center. Dr Blue's clinical interests include treatment of plasma cell disorders and evaluation of patients pre and post bone marrow transplant. His research interests include reducing health disparities and improving health outcomes for plasma cell dyscrasias.

Care Philosophy: Dr Chadha is an Assistant Professor at the University of South Florida, Morsani College of Medicine. After graduating from New York University, he completed his medical degree from the New York Institute of Technology College of Osteopathic Medicine and completed an Internal Medicine Residency at Icahn School of Medicine at Mount Sinai. Most recently, he completed a Hematology/Oncology Fellowship at the Donald and Barbara Zucker School of Medicine at Hofstra Northwell Health Lenox Hill Hospital. Dr Chadha's focus is solid tumor oncology, with clinical interests in genitourinary tract tumors, including prostate cancer, bladder cancer, kidney cancer, testicular cancer, and thoracic malignancies.